Pharmaceuticals Search Engine [selected websites]


Thursday, November 22, 2007

BioAlliance Pharma, pivotal phase III clinical trial of Loramyc , treatment of oropharyngeal candidiasis

Paris, November 16, 2007 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc® in the US, for the treatment of oropharyngeal candidiasis... [PDF] BioAlliance's Press Release - PDF en Français -

NicOx’ naproxcinod phase 3 results

Sophia Antipolis, France, Nov. 22, 2007 - ...Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United-States during the first quarter of 2009... [PDF] NicOx’ Press Release - PDF en Français -